APIMEDS PHARMACEUTICALS US, INC. Operating Cash Flow
APIMEDS PHARMACEUTICALS US, INC. (APUS) reported Operating Cash Flow of -$7.73 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-14
- APIMEDS PHARMACEUTICALS US, INC. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$5.67M.
- APIMEDS PHARMACEUTICALS US, INC. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$2.07M.
- APIMEDS PHARMACEUTICALS US, INC. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$3.82M.
- APIMEDS PHARMACEUTICALS US, INC. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$1.73M.
- APIMEDS PHARMACEUTICALS US, INC. net cash provided by (used in) operating activities for fiscal 2025 was -$8.93M.
- APIMEDS PHARMACEUTICALS US, INC. net cash provided by (used in) operating activities for fiscal 2024 was -$733.53K.
- APIMEDS PHARMACEUTICALS US, INC. net cash provided by (used in) operating activities for fiscal 2023 was -$627.79K.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$5.67M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | -$7.73M 10-Q · filed 2026-08-14 | -$11.55M derived: sum of 3 quarters · filed 2026-08-14 | -$13.28M derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | -$2.07M 10-Q · filed 2026-05-26 | -$5.89M derived: sum of 2 quarters · filed 2026-05-26 | -$7.61M derived: sum of 3 quarters · filed 2026-05-26 | -$10.97M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-12-31 | -$3.82M derived: 10-K 12 month − 10-Q 9 month · filed 2026-05-04 | -$5.54M derived: sum of 2 quarters · filed 2026-05-04 | -$8.91M derived: sum of 3 quarters · filed 2026-08-14 | -$8.93M 10-K · filed 2026-05-04 |
| 2025-09-30 | -$1.73M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$5.09M derived: sum of 2 quarters · filed 2026-08-14 | -$5.11M 10-Q · filed 2025-11-12 | -$5.21M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-06-30 | -$3.36M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | -$3.38M 10-Q · filed 2026-08-14 | -$3.48M derived: sum of 3 quarters · filed 2026-08-14 | -$3.67M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-03-31 | -$20.31K 10-Q · filed 2026-05-26 | -$119.93K derived: sum of 2 quarters · filed 2026-05-26 | -$306.68K derived: sum of 3 quarters · filed 2026-05-26 | -$490.74K derived: sum of 4 quarters · filed 2026-05-26 |
| 2024-12-31 | -$99.62K derived: 10-K 12 month − 10-Q 9 month · filed 2026-05-04 | -$286.37K derived: sum of 2 quarters · filed 2026-05-04 | -$470.43K derived: sum of 3 quarters · filed 2026-05-04 | -$733.53K 10-K · filed 2026-05-04 |
| 2024-09-30 | -$186.75K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$370.81K derived: sum of 2 quarters · filed 2025-11-12 | -$633.91K 10-Q · filed 2025-11-12 | |
| 2024-06-30 | -$184.06K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-19 | -$447.15K 10-Q · filed 2025-08-19 | ||
| 2024-03-31 | -$263.10K 10-Q · filed 2025-05-20 | |||
| 2023-12-31 | -$627.79K 10-K · filed 2025-04-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |